Gordon, J. K., Magid, S. K., Maki, R. G., Fleisher, M., Berman, E. (June 2010) Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res, 34 (6). pp. 827-9. ISSN 1873-5835 (Electronic)0145-2126 (Linking)
Abstract
Imatinib mesylate is used with increasing frequency and duration for the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST), and other neoplastic conditions. Although muscular complaints are common, elevations of creatine kinase (CK) are listed as <1% in the product label. We describe here a case of rhabdomyolysis likely related to imatinib as well as the results of a prospective evaluation of CK levels in a cohort of patients on imatinib for CML or GIST. We found a high prevalence of CK abnormalities in this group and believe that CKs should be monitored during therapy with imatinib.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | Adult Aged Antineoplastic Agents/adverse effects/therapeutic use Benzamides Case-Control Studies Cohort Studies Creatine Kinase/*blood Edema/blood/chemically induced Female Gastrointestinal Stromal Tumors/blood/drug therapy Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*blood/drug therapy Male Middle Aged Muscular Diseases/blood/chemically induced Piperazines/adverse effects/*therapeutic use Pyrimidines/adverse effects/*therapeutic use Up-Regulation/drug effects Young Adult |
| Subjects: | diseases & disorders > cancer > drugs and therapies diseases & disorders > cancer > cancer types > gastrointestinal stromal tumors diseases & disorders > cancer > cancer types > leukemia |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matt Covey |
| Date: | June 2010 |
| Date Deposited: | 21 Oct 2016 19:51 |
| Last Modified: | 21 Oct 2016 19:51 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/33708 |
Actions (login required)
 |
Administrator's edit/view item |